MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 27, 2006; DOI: 10.1124/mol.105.021253


0026-895X/06/6905-1684-1691$20.00
Mol Pharmacol 69:1684-1691, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.021253v1
69/5/1684    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamashita, N.
Right arrow Articles by Ono, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamashita, N.
Right arrow Articles by Ono, K.

Short- and Long-Term Amiodarone Treatments Regulate Cav3.2 Low-Voltage-Activated T-type Ca2+ Channel through Distinct Mechanisms

Noboru Yamashita, Toshihiko Kaku, Tomoko Uchino, Shojiro Isomoto, Hironobu Yoshimatsu, and Katsushige Ono

Department of Cardiovascular Science (N.Y., T.K., T.U., S.I., K.O.) and Internal Medicine (N.Y., H.Y.), Oita University School of Medicine, Oita, Japan

Low-voltage-activated T-type Ca2+ channels have been recognized recently in the mechanisms underlying atrial arrhythmias. However, the pharmacological effects of amiodarone on the T-type Ca2+ channel remain unclear. We investigated short- and long-term effects of amiodarone on the T-type (Cav 3.2) Ca2+ channel. The Cav3.2 {alpha}1H subunit derived from human heart was stably transfected into cells [human embryonic kidney (HEK)-Cav3.2] cultured with or without 5 µM amiodarone. Patch-clamp recordings in the conventional whole-cell configuration were used to evaluate the actions of amiodarone on the T-type Ca2+ channel current (ICa.T). Amiodarone blockade of ICa.T occurred in a dose- and holding potential-dependent manner, shifting the activation and the steady-state inactivation curves in the hyperpolarization direction, when amiodarone was applied immediately to the bath solution. However, when the HEK-Cav3.2 cells were incubated with 5 µM amiodarone for 72 h, ICa.T density was significantly decreased by 31.7 ± 2.3% for control,-93.1 ± 4.3 pA/pF (n = 8), versus amiodarone,-56.5 ± 3.2 pA/pF (n = 13), P < 0.001. After the prolonged administration of amiodarone, the activation and the steadystate inactivation curves were shifted in the depolarization direction by -7.1 (n = 41) and -5.5 mV (n = 37), respectively, and current inactivation was significantly delayed [time constant ({tau}): control, 13.3 ± 1.1 ms (n = 6) versus amiodarone, 39.6 ± 5.5 ms (n = 6) at -30 mV, P < 0.001)]. Nevertheless, short-term inhibitory effects of amiodarone on the modified T-type Cav3.2 Ca2+ channel created by long-term amiodarone treatment were functionally maintained. We conclude that amiodarone exerts its short- and long-term inhibitory actions on ICa.T via distinct blocking mechanisms.


Received November 28, 2005; accepted January 26, 2006

Address correspondence to: Dr. Katsushige Ono, Department of Cardiovascular Science, Oita University School of Medicine, 1-1 Idaigaoka, Hasama, Yufu, Oita 879-5593, Japan. E-mail: ono{at}med.oita-u.ac.jp




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Wu, S. Rajamani, J. C. Shryock, H. Li, J. Ruskin, C. Antzelevitch, and L. Belardinelli
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone
Cardiovasc Res, February 1, 2008; 77(3): 481 - 488.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics